JP5007003B2 - 富化された中枢神経系の幹細胞および始原細胞の集団、ならびにこのような集団を同定、単離、および富化するための方法 - Google Patents

富化された中枢神経系の幹細胞および始原細胞の集団、ならびにこのような集団を同定、単離、および富化するための方法 Download PDF

Info

Publication number
JP5007003B2
JP5007003B2 JP2000598656A JP2000598656A JP5007003B2 JP 5007003 B2 JP5007003 B2 JP 5007003B2 JP 2000598656 A JP2000598656 A JP 2000598656A JP 2000598656 A JP2000598656 A JP 2000598656A JP 5007003 B2 JP5007003 B2 JP 5007003B2
Authority
JP
Japan
Prior art keywords
cells
monoclonal antibody
population
cell
pta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000598656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002536023A5 (cg-RX-API-DMAC10.html
JP2002536023A (ja
Inventor
デイビッド ダブリュー． バック，
ノブコ ウチダ，
アービング ウェイスマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
StemCells California Inc
Original Assignee
StemCells California Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/422,844 external-priority patent/US6468794B1/en
Application filed by StemCells California Inc filed Critical StemCells California Inc
Publication of JP2002536023A publication Critical patent/JP2002536023A/ja
Publication of JP2002536023A5 publication Critical patent/JP2002536023A5/ja
Application granted granted Critical
Publication of JP5007003B2 publication Critical patent/JP5007003B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2000598656A 1999-02-12 2000-02-11 富化された中枢神経系の幹細胞および始原細胞の集団、ならびにこのような集団を同定、単離、および富化するための方法 Expired - Lifetime JP5007003B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11972599P 1999-02-12 1999-02-12
US09/422,844 US6468794B1 (en) 1999-02-12 1999-10-21 Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US16840799P 1999-12-01 1999-12-01
US09/422,844 1999-12-01
US60/168,407 1999-12-01
US60/119,725 1999-12-01
PCT/US2000/003592 WO2000047762A2 (en) 1999-02-12 2000-02-11 Enriched central nervous system cell populations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010173169A Division JP2010252808A (ja) 1999-02-12 2010-07-30 富化された中枢神経系の幹細胞および始原細胞の集団、ならびにこのような集団を同定、単離、および富化するための方法

Publications (3)

Publication Number Publication Date
JP2002536023A JP2002536023A (ja) 2002-10-29
JP2002536023A5 JP2002536023A5 (cg-RX-API-DMAC10.html) 2007-03-29
JP5007003B2 true JP5007003B2 (ja) 2012-08-22

Family

ID=46844555

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000598656A Expired - Lifetime JP5007003B2 (ja) 1999-02-12 2000-02-11 富化された中枢神経系の幹細胞および始原細胞の集団、ならびにこのような集団を同定、単離、および富化するための方法
JP2010173169A Withdrawn JP2010252808A (ja) 1999-02-12 2010-07-30 富化された中枢神経系の幹細胞および始原細胞の集団、ならびにこのような集団を同定、単離、および富化するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010173169A Withdrawn JP2010252808A (ja) 1999-02-12 2010-07-30 富化された中枢神経系の幹細胞および始原細胞の集団、ならびにこのような集団を同定、単離、および富化するための方法

Country Status (10)

Country Link
US (1) US20070238171A1 (cg-RX-API-DMAC10.html)
EP (2) EP1900811B1 (cg-RX-API-DMAC10.html)
JP (2) JP5007003B2 (cg-RX-API-DMAC10.html)
AT (2) ATE377652T1 (cg-RX-API-DMAC10.html)
AU (2) AU780256B2 (cg-RX-API-DMAC10.html)
CA (1) CA2361249C (cg-RX-API-DMAC10.html)
DE (2) DE60044655D1 (cg-RX-API-DMAC10.html)
DK (2) DK1900811T3 (cg-RX-API-DMAC10.html)
ES (2) ES2351170T3 (cg-RX-API-DMAC10.html)
WO (1) WO2000047762A2 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
DE60044655D1 (de) * 1999-02-12 2010-08-19 Stemcells California Inc Angereicherte Zellpopulationen des zentralen Nervensystems
US20050042749A1 (en) 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
US7250294B2 (en) 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
EP1287116A2 (en) 2000-05-17 2003-03-05 Geron Corporation Neural progenitor cell populations
WO2002097069A1 (en) * 2001-06-01 2002-12-05 University Of Sydney Purification of lineage-specific cells and uses therefor
AUPR540301A0 (en) * 2001-06-01 2001-06-28 Walter And Eliza Hall Institute Of Medical Research, The A method of purification of cells
ATE371018T1 (de) 2001-06-22 2007-09-15 Stemcells Inc Le-zellen (liver engrafting cells), assays und verwendungen davon
US7381561B2 (en) 2002-08-27 2008-06-03 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
JP4481706B2 (ja) * 2004-03-31 2010-06-16 独立行政法人科学技術振興機構 脳梗塞疾患モデルマウス
WO2008064408A1 (en) * 2006-11-27 2008-06-05 The University Of Queensland Generation of enriched populations of neural progenitor cells and their progeny
DK2114167T3 (en) * 2007-01-16 2018-09-17 Univ Rochester NON-HUMAN ANIMALS WITH HUMAN GLIAKIMARY BRAIN
JP5035928B2 (ja) * 2009-12-15 2012-09-26 独立行政法人産業技術総合研究所 ヒト神経幹細胞のスクリーニング方法
JP4997613B2 (ja) * 2009-12-15 2012-08-08 独立行政法人産業技術総合研究所 ヒト神経幹細胞に選択的なモノクローナル抗体及びこれを用いたスクリーニング方法
JP6090735B2 (ja) * 2012-03-02 2017-03-08 国立大学法人山口大学 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
ES2927175T3 (es) 2013-02-12 2022-11-03 Reneuron Ltd Método de producción de micropartículas
TWI482782B (zh) * 2013-05-31 2015-05-01 Univ Nat Chiao Tung 架接抗體之雙乳化核殼奈米結構
EP4526433A4 (en) * 2022-05-20 2026-05-06 Univ Leland Stanford Junior METHODS FOR ISOLATING NUAL AND PROGENITOR STEM CELLS FROM THE DEVELOPING HUMAN BRAIN

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001159A1 (en) * 1997-07-04 1999-01-14 University Of Utah Research Foundation Lineage-restricted neuronal precursors
WO1999037751A1 (en) * 1998-01-23 1999-07-29 Imclone Systems Incorporated Purified populations of stem cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
JPH08500245A (ja) * 1992-07-27 1996-01-16 カリフォルニア インスティテュート オブ テクノロジー 哺乳動物の多能性神経幹細胞
IT1264903B1 (it) 1993-06-30 1996-10-17 Sniaricerche S C P A Cristalli liquidi metallo-organici in una matrice polimerica
US5843633A (en) * 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6451306B1 (en) * 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
WO2000012683A2 (en) * 1998-08-31 2000-03-09 New York University Stem cells bearing an fgf receptor on the cell surface
DE60044655D1 (de) * 1999-02-12 2010-08-19 Stemcells California Inc Angereicherte Zellpopulationen des zentralen Nervensystems
US7037719B1 (en) * 1999-02-12 2006-05-02 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US6468794B1 (en) * 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US7105150B2 (en) * 1999-02-12 2006-09-12 Stemcells California, Inc. In vivo screening methods using enriched neural stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001159A1 (en) * 1997-07-04 1999-01-14 University Of Utah Research Foundation Lineage-restricted neuronal precursors
WO1999037751A1 (en) * 1998-01-23 1999-07-29 Imclone Systems Incorporated Purified populations of stem cells

Also Published As

Publication number Publication date
DE60037007T2 (de) 2008-08-21
ATE473273T1 (de) 2010-07-15
DE60044655D1 (de) 2010-08-19
EP1144671A2 (en) 2001-10-17
WO2000047762A9 (en) 2002-04-11
ES2351170T3 (es) 2011-02-01
ES2295012T3 (es) 2008-04-16
CA2361249C (en) 2011-05-10
EP1144671B1 (en) 2007-11-07
AU3361800A (en) 2000-08-29
WO2000047762A3 (en) 2000-12-21
DK1900811T3 (da) 2010-10-25
JP2010252808A (ja) 2010-11-11
US20070238171A1 (en) 2007-10-11
EP1900811B1 (en) 2010-07-07
EP1900811A1 (en) 2008-03-19
DK1144671T3 (da) 2008-03-17
CA2361249A1 (en) 2000-08-17
AU2005202534A1 (en) 2005-07-07
WO2000047762A2 (en) 2000-08-17
AU780256B2 (en) 2005-03-10
AU2005202534B2 (en) 2008-05-08
ATE377652T1 (de) 2007-11-15
DE60037007D1 (de) 2007-12-20
JP2002536023A (ja) 2002-10-29

Similar Documents

Publication Publication Date Title
US7153686B2 (en) Compositions of enriched central nervous system stem cell and progenitor cell populations
JP2010252808A (ja) 富化された中枢神経系の幹細胞および始原細胞の集団、ならびにこのような集団を同定、単離、および富化するための方法
US8241897B2 (en) Isolation of neural stem cells using gangliosides and other surface markers
JP2007503815A (ja) 富化された膵臓幹細胞および前駆細胞集団、ならびにこれらの集団の同定、単離および富化方法
JP2012120545A (ja) 細胞を精製する方法
JP2004538490A (ja) 体性幹細胞の同定および単離ならびにその使用
AU2003278741B2 (en) Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
CN108588025A (zh) 人视网膜祖细胞的表型谱
AU2002308446A1 (en) A method of purification cells
US7105150B2 (en) In vivo screening methods using enriched neural stem cells
Hunter et al. Bipotential glial progenitors are targets of neuronal cell line-derived growth factors
US7037719B1 (en) Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US20050202516A1 (en) Methods and compositions for neural progenitor cells
US7217565B2 (en) Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US20100086998A1 (en) Enriched Central Nervous System Stem Cell and Progenitor Cell Populations, and Methods For Identifying, Isolating and Enriching For Such Populations
Schubert et al. Characterization and distribution of a new cell surface marker of neuronal precursors
JP5643187B2 (ja) 前駆細胞を認識するモノクローナル抗体を産生するための方法
WO2009086333A2 (en) Antibodies and methods for identifying and tracking engraftment, migratation, and differentiation of human stem, progenitor, and engrafting cell populations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110721

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20111019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120501

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120528

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150601

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5007003

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term